Daridorexant
Extensively StudiedBest-in-class dual orexin receptor antagonist for next-day cognition: 8-hour half-life clears before morning, preserves N3/REM sleep… | Pharmaceutical · Oral
Aliases (4)
▸Brand options2 known
StatusSchedule IV (US DEA, effective 2022-04-07) | Class B/POM equivalent (EU, approved 2022-04) | Rx-only most jurisdictions
▸ Overview TL;DR
Best-in-class dual orexin receptor antagonist for next-day cognition: 8-hour half-life clears before morning, preserves N3/REM sleep architecture (unlike Z-drugs/benzos), shows strongest total-sleep-time signal at 50 mg in 2025 NMA, and has no rebound insomnia or withdrawal through 12 months. For Dylan: WATCH-LIST not PRIMARY — his issue is a delayed chronotype, not insomnia, and DORAs lower wake drive but don't shift the circadian phase. Reserve as the escalation step if 4-6 weeks of l-tryptophan + magnesium + dim-light hygiene + 0.3-0.5 mg early-evening melatonin fails to migrate bedtime to midnight, OR if WASO/sleep maintenance becomes a real complaint after V5 modafinil onboarding stresses sleep.
▸ Mechanism of action
Daridorexant is a competitive, reversible antagonist at both orexin receptors (OX1 and OX2) — a "DORA" in the modern nomenclature.
The orexin system in plain English: Orexin (also called hypocretin) is a hypothalamic neuropeptide that functions as the brain's "stay awake" master switch. Orexin neurons live in the lateral hypothalamus, fire vigorously during wakefulness, fall silent during sleep, and project broadly to every wake-promoting nucleus in the brain — locus coeruleus (norepinephrine), tuberomammillary nucleus (histamine), raphe (serotonin), VTA (dopamine), basal forebrain (acetylcholine). When orexin neurons fire, they keep all these wake systems online. When they shut up, sleep happens.
Two receptor subtypes:
- OX1 (HCRTR1): preferential for orexin-A; concentrated in locus coeruleus → drives arousal/vigilance/sympathetic tone.
- OX2 (HCRTR2): binds both orexin-A and orexin-B; concentrated in tuberomammillary nucleus → drives wakefulness/histamine cascade. OX2 blockade is the dominant sleep-promoting pathway; OX1 contributes secondary.
Why DORAs are mechanistically cleaner than GABAergic hypnotics:
- Z-drugs (zolpidem) and benzos work by forcing GABA-A activation everywhere — including circuits that have nothing to do with sleep. Result: sedation that overrides normal sleep architecture, suppresses REM and N3 (deep) sleep, blunts memory consolidation, produces next-day cognitive impairment, and creates tolerance + dependence over weeks.
- DORAs work by removing one input to the wake circuit — not by adding sedative pressure. The brain's endogenous sleep-promoting circuits (VLPO, melanin-concentrating hormone neurons, adenosine accumulation) then drive sleep on their own, with their own architecture. Sleep is "permitted" rather than "forced."
Daridorexant-specific features:
- Half-life ~8 hours — deliberately designed to align with a normal sleep window. Suvorexant is 12 hr, lemborexant is 17-19 hr. The 8-hour half-life is daridorexant's central engineering claim: enough to last the night, gone by morning.
- CYP3A4-dominant metabolism (~89% of clearance) — clinically relevant for stack design (see Drug Interactions).
- No clinically meaningful active metabolites at therapeutic doses — clean PK profile.
- Preserves sleep architecture in PSG studies (post-hoc analysis of phase 3 data, Sleep 2024): no alteration of N2/N3/REM EEG spectra, no change in sleep spindles, dose-dependent reduction in N1 (light, fragmented sleep) and increases in N2/N3/REM (consolidated, restorative sleep). This is the architecture profile a brain-priority user wants — most hypnotics suppress N3 and/or REM.
Idorsia development context: Idorsia Pharmaceuticals (Swiss spin-off from Actelion 2017) developed daridorexant after spending the late 2010s searching for an OX1/OX2 dual antagonist with a tight half-life window. ACT-541468 (later daridorexant) was selected from ~12,000 candidates specifically for the 8-hour half-life property. FDA approved 2022-01-07; DEA scheduled IV 2022-04-07; EMA approved 2022-04-29. Real-world EU rollout has been slower than anticipated, putting financial pressure on Idorsia (relevant if you care about long-term supply continuity).
▸ Pharmacokinetics No data
▸Research indications1 use cases
Half-life ~8 hours
Most effectivedeliberately designed to align with a normal sleep window. Suvorexant is 12 hr, lemborexant is 17-19 hr. The 8-hour half-life is daridore…
▸Research protocols2 protocols
| Goal | Dose | Frequency | Solo | Cycle |
|---|---|---|---|---|
| Avoid food in the hour before | 25 mg doses (10 mg in the phase 3 trials) failed to separate from placebo on primary endpoints | — | — | — |
| PRN use is fine | — | — | — | — |
Auto-extracted from dosing notes. For full context including caveats and Dylan-specific protocols, see the Dosing protocols section.
▸Quality indicators4 checks
▸ What to expect From notes
- 1Onset~30-60 min to perceptible relaxation; Tmax ~1-2 hr (food delays Tmax modestly but doesn't change AUC meani…
- 2Peak~1-3 hours after dose. The feel is "reduced wakefulness drive," not sedation. Most users describe it as: t…
▸ Side effects + safety Tabbed view
Common (>10% users)
- Headache — ~5-10% (lower than the 30%+ seen with modafinil). Usually fades within a week.
- Somnolence / fatigue next-day — ~6% at 50 mg, ~4% at 25 mg. More likely in the first week. The 2025 Sleep Medicine paper actually showed less next-morning sleepiness vs placebo on average — but the individual variability matters.
Less common (1-10%)
- Dizziness — ~2-3%, mostly first week.
- Nausea — uncommon but reported.
- Nasopharyngitis — most common TEAE in the 12-month extension (likely incidental, similar rate as placebo).
Rare-serious (<1% but worth knowing)
- Sleep paralysis — rare in trials (1-2 patients per study arm at 25-50 mg). Manifests as inability to move/speak for seconds-to-minutes during sleep-wake transitions. Almost always benign and self-limited but disturbing if you don't know what it is. Watch period: any time on drug; tends to occur in the first weeks.
- Hypnagogic / hypnopompic hallucinations — vivid perceptions on falling asleep or waking. Reported in ~1-2% of trial subjects. Generally not distressing but disqualifying for users prone to anxiety around sleep.
- Cataplexy-like leg weakness — rare, transient (seconds to minutes). Theoretically linked to OX2 blockade in the brainstem REM-atonia circuits (orexin-deficient narcolepsy patients have cataplexy; pharmacologic orexin blockade produces a milder, dose-dependent version in a tiny subset). Triggered (or not) by laughter/surprise. No complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) reported in trials — a meaningful safety advantage over zolpidem.
- Compromised respiratory function in severe OSA — labeling caution. Mild-moderate OSA was studied and was fine; severe OSA still flagged. Not relevant for Dylan but worth noting.
- Suicidal ideation — class warning across all CNS depressants in US labeling; no signal specific to daridorexant.
- Driving impairment next-day at 50 mg — modest, dose-dependent, especially first week. Don't drive in the morning if you feel residual.
Specific watch periods
- First 2 weeks: parasomnia/sleep paralysis/hallucination watch. Most reports cluster early. If any disturbing parasomnia → stop, don't titrate up.
- First month at 50 mg: next-day function watch. If grogginess persists beyond 2 weeks at 50 mg, drop back to 25 mg.
▸Interactions12 compounds
- l-tryptophanSynergisticTryptophan feeds the melatonin pathway (substrate-side), daridorexant lowers wake drive (receptor-side). They work on different mechanisms with non-overlappi…
- Magnesium glycinateSynergistic(already V4): NMDA modulation + glycinergic relaxation. Mechanistically independent. Safe stack.
- ApigeninSynergistic(already V4): GABA-A PAM at low doses. Theoretically additive but in practice neither produces strong sedation alone — combining is fine.
- L-theanineSynergistic(already V4): GABA modulation + glutamate downregulation. Compatible.
- AlcoholAvoidPhase 1 study (PMID 33205362) shows additive PD impairment (saccadic velocity, body sway, alertness). FDA labeling says don't combine. For Dylan zero-alcohol…
- Strong CYP3A4 inhibitorsAvoid(clarithromycin, ketoconazole, itraconazole, ritonavir, nefazodone, grapefruit juice in large quantities): AVOID — daridorexant exposure can rise 4-5×. Label…
- Moderate CYP3A4 inhibitorsAvoid(diltiazem, erythromycin, fluconazole, fluvoxamine, verapamil, ciprofloxacin): Maximum 25 mg dose. Don't titrate to 50 mg.
- Strong CYP3A4 inducersAvoid(carbamazepine, phenytoin, rifampin, St. John's wort, efavirenz, apalutamide, enzalutamide): efavirenz alone reduced AUC by 61%. Daridorexant becomes ineffec…
- Other CNS depressantsAvoid(benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB): additive sedation and respiratory risk. Don't double-stack hypnotics.
- BromantaneAvoid(in V5 plan): not a hard contraindication but conceptually contradictory the same evening — bromantane upregulates dopamine synthesis (wake-supportive), dari…
- ModafinilAvoidsame calendar day: pharmacokinetically fine (modafinil is mostly cleared by CYP3A4 induction effects but doesn't significantly inhibit), but functionally red…
- SelankAvoidsame evening: mechanistically theta-rhythm modulation; shouldn't dangerous-stack but probably blunts daridorexant's sleep-permitting effect because Selank is…
▸References20 sources
Daridorexant: First Approval (Markham, Drugs 2022)
2022definitive first-approval review, PK/PD, regulatory history.
Mignot et al., Lancet Neurology 2022 — pivotal phase 3 trials
20221,854 patients across 18 countries; co-primary endpoints WASO and LPS.
Mignot et al., CNS Drugs 2022 — 12-month long-term safety extension
2022804 patients, 40 weeks, no rebound or withdrawal.
Quviviq US prescribing information (FDA label)
definitive dosing, contraindications, drug interactions.
Bartoli et al., Translational Psychiatry 2025 — DORA NMA
2025head-to-head efficacy across daridorexant, lemborexant, suvorexant. DAR50 strongest for TST; LEM10 strongest for sleep onset.
Sleep architecture pooled analysis (academic.oup.com/sleep, 2024)
2024N3/REM/spindle preservation, dose-dependent N1 reduction.
Next-morning sleepiness analysis, Sleep Medicine 2025
2025daridorexant *decreased* next-morning sleepiness vs placebo.
DEA Schedule IV placement, Federal Register 2022-04-07
2022abuse-liability comparable to suvorexant/zolpidem; less drug-liking than zolpidem 30 mg.
Daridorexant abuse potential preclinical, PMC10714714
rat self-administration, intracranial-self-stimulation: no evidence of abuse-liking signal beyond reference comparators.
CYP3A4 metabolism characterization, ChemMedChem 2023
202389% CYP3A4 dependence; intramolecular rearrangement mechanism.
Daridorexant + ethanol PK/PD interaction, PMID 33205362
additive PD impairment, modest PK shift; "do not combine" labeling rationale.
Daridorexant + citalopram PK/PD interaction, J Psychopharmacology 2021
2021no clinically meaningful interaction.
Real-world retrospective single-center study, PMC11176093
confirms phase-3 efficacy in routine clinical practice.
Drugs.com user reviews (n=182, 2024-2026)
20245.4/10 average; 40% positive, 43% negative. Polarized response pattern.
Quviviq cost / GoodRx 2026
2026current US retail and discount pricing.
Quviviq manufacturer savings card
Idorsia QSavings Card details.
Seltorexant Phase 3 announcement, J&J 2024-2025
2024selective OX2 antagonist for MDD + insomnia comorbid; comparator for class evolution.
Orexin receptor antagonists for AD prevention, Drugs 2024
2024speculative long-term cognitive/AD-modifying potential.
Orexin system + cognition review, npj Biological Timing and Sleep 2025
2025chronic OX1R blockade animal-data concerns; relevant for healthy-young user calculus.
Idorsia daridorexant product monograph
manufacturer technical document.